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Endosialin is a transmembrane glycoprotein selectively expressed in blood vessels and stromal fibroblasts of various human tumours.
It has been functionally implicated in angiogenesis, but the factors that control its expression have remained unclear. As insufficient
delivery of oxygen is a driving force of angiogenesis in growing tumours, we investigated whether hypoxia regulates endosialin
expression. Here, we demonstrate that endosialin gene transcription is induced by hypoxia predominantly through a mechanism
involving hypoxia-inducible factor-2 (HIF-2) cooperating with the Ets-1 transcription factor. We show that HIF-2 activates the
endosialin promoter both directly, through binding to a hypoxia-response element adjacent to an Ets-binding site in the distal part of
the upstream regulatory region, and indirectly, through Ets-1 and its two cognate elements in the proximal promoter. Our data also
suggest that the SP1 transcription factor mediates responsiveness of the endosialin promoter to high cell density. These findings
elucidate important aspects of endosialin gene regulation and provide a rational frame for future investigations towards better
understanding of its biological significance.
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Endosialin (alternatively named TEM1 or CD248) is a highly
glycosylated single-pass transmembrane protein proposed to
become a marker of tumour vasculature and a target for anticancer
therapy (Teicher, 2007). Endosialin was discovered with a
monoclonal antibody (MAb) raised against human foetal fibro-
blasts as an antigen selectively expressed in tumour blood vessels
and absent in normal human tissues (Rettig et al, 1992).
Independently, TEM1 (tumour endothelial marker 1) was linked
to tumour endothelium by serial analysis of gene expression
(St Croix et al, 2000). Identity of endosialin with TEM1 was then
demonstrated by Christian et al (2001), who cloned its full-length
cDNA, and based on the domain composition and homology to
thrombomodulin classified endosialin as a C-type lectin-like
receptor.
Subsequent studies have confirmed that endosialin is upregu-
lated in blood vessels and activated stromal fibroblasts in human
colorectal, brain and breast tumours as well as in mouse xenograft
models (Carson-Walter et al, 2001; Brady et al, 2004; Davies et al,
2004; Madden et al, 2004; Dolznig et al, 2005; MacFadyen et al,
2005, 2007; Huber et al, 2006; Rupp et al, 2006). Endosialin
expression is restricted to capillaries and shows a heterogeneous
pattern typical for molecules involved in vascular reorganisation.
Moreover, abundant endosialin expression was found in the
vasculature and fibroblast-like cells of the developing mouse and
human embryos (Rupp et al, 2006; MacFadyen et al, 2007;
Virgintino et al, 2007). Using a gene targeting approach, Nanda
et al (2006) have shown that endosialin is dispensable for normal
development and subcutaneous tumour growth, but can modulate
invasiveness and metastatic progression in an orthotopic xenograft
model of colorectal cancer. All these data support the functional
involvement of endosialin in angiogenesis, a complex process of
vascular branching and sprouting that plays a key role in tumour
expansion and progression, and therefore represents an opportu-
nity for therapeutic intervention against cancer.
Recent antiangiogenic strategies are based on targeting the
molecules selectively expressed in tumour vessels (Fukumura and
Jain, 2007). From this viewpoint, expression pattern and possible
functional implication in angiogenesis make endosialin a promis-
ing subject of clinical investigations. However, present research
suffers from inadequate knowledge of factors and pathways that
control endosialin expression and determine its tissue distribution.
There is only a single study showing that mouse endosialin gene
transcription is induced by high cell density, but the underlying
molecular mechanism has not been elucidated (Opavsky et al,
2001).
Angiogenesis is well known to be principally driven by hypoxia
in growing solid tumours as well as in developing embryos (Liao
and Johnson, 2007). Hypoxia often develops in intratumoral areas
with deficient or functionally inadequate blood vessels. Insufficient
delivery of oxygen then promotes multiple adaptive responses
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sincluding angiogenesis, which facilitates new blood supply and
allows for further tumour expansion (Harris, 2002). This adapta-
tion process is governed by hypoxia-inducible transcription
factors, notably HIF-1 and HIF-2. In normoxia, the a-subunits of
HIFs are modified by oxygen-dependent prolyl hydroxylases
(PHDs), interact with the von Hippel-Lindau tumour-suppressor
protein, and undergo rapid ubiquitination and proteasome-
mediated degradation. Hypoxia leads to inactivation of PHDs,
stabilisation of the a-subunits, their translocation into the
nucleus, heterodimerisation with the constitutive b-subunit, and
formation of an active transcription complex (Ruas and Poellinger,
2005). Hypoxia-inducible factors can transactivate a large
spectrum of genes contributing to adaptation, including proangio-
genic factors VEGF (vascular endothelial growth factor), ANG2
(angiopoietin 2) and their receptors (Hickey and Simon, 2006;
Ruas et al, 2007).
Here, we provide the first evidence that hypoxia induces
expression of endosialin predominantly through the HIF-2
transcription factor. We have identified cis-elements in the
upstream regulatory region of the human endosialin gene that
mediate the hypoxic responses and demonstrate that these
elements bind HIF-2 in both direct and indirect manners.
Moreover, we show that upregulation of endosialin by high cell
density is mediated by the SP1 transcription factor and is partly
caused by pericellular hypoxia. Thus, these combined transcrip-
tional regulatory mechanisms are important for intratumoral
expression of endosialin.
MATERIALS AND METHODS
Cell culture
All cell lines, including human HeLa cervical carcinoma cells, 42-
MG-BA glioblastoma cells (Perzelova ´ et al, 1998), FIB-3 placental
fibroblasts, mouse NIH3T3 fibroblasts, b.END3 brain endothelial
cells and the HIF-1b-deficient Hepa-1c4 hepatoma cells (Legraver-
end et al, 1982) were cultured in DMEM with 10% FCS (BioWhit-
taker, Verviers, Belgium) in a humidified atmosphere with 5% CO2
at 371C. The cells were exposed to hypoxia (2% O2)i na na n a e r o b i c
workstation (Ruskinn Technology, Bridgend, UK) in 5% CO2,2 %H 2
and 91% N2 at 371C. Hypoxia was also induced chemically with
100mM 2,20-dipyridyl (DIP, Sigma, St Louis, MO, USA).
Reporter promoter constructs
The endosialin-luc promoter construct was generated by an
insertion of a  1091/þ43 endosialin genomic region amplified
by PCR upstream of the firefly luciferase gene in pGL3-basic
luciferase reporter vector (Promega, Madison, WI, USA). Deletion
and mutant variants of the promoter were generated from this
construct by PCR using the primers mentioned in the Supple-
mentary information. Deletion variant  285/þ43 was created by
SacI digestion.
Expression plasmids
Human HIF-1a and mouse HIF-2a cDNAs in pcDNA1/Neo
plasmid were kindly provided by Professor Patrick Maxwell,
Imperial College of Science, Technology and Medicine, London,
UK. Expression plasmid pCMV-HIF-1b containing human HIF-1b/
ARNT cDNA was described previously (Whitelaw et al, 1993).
Expression plasmids CMV-Sp1 containing human SP1 cDNA and
SP(RSV)AP-2 containing human TFAP2A/AP-2 cDNA were
purchased from Addgene (Cambridge, MA, USA). pcDNA3.1/
Neo/Ets-1 expression plasmid was created by insertion of 1571bp
human Ets-1 cDNA fragment amplified by RT–PCR into
pcDNA3.1(þ) (Invitrogen, Carlsbad, CA, USA). Human endosia-
lin cDNA was amplified using endosialin_F1 and endosialin_R1
primers and cloned into phCMV1 expression vector (Genlantis,
San Diego, CA, USA). For prokaryotic expression, the endosialin
cDNA fragment encoding the amino acids 192–675 was amplified
and cloned into pGEX-4T-1 plasmid (Amersham Biosciences,
Chalfont St Giles, UK).
Generation of endosialin-specific MAb
BALB/c mice were immunised with two doses of 5 10
6 HeLa cells
transfected with endosialin cDNA in a phCMV1 expression vector
and boosted with 100mg GST-endosialin protein bound to
Glutathione Sepharose 4B. Fusion of spleen cells with Sp2/0
myeloma cells was carried out 3 days later. Monoclonal antibodies
produced by the hybridomas were screened for the specific
reactivity towards endosialin protein in HeLa-endosialin vs HeLa-
mock cells by ELISA and immunoblotting. The hybridoma culture
(M78) was subcloned by limiting dilution, expanded and used for
the MAb production.
RNA isolation and reverse transcription PCR
Total RNA was extracted from cells using the NucleoSpin RNA II
kit (Macherey-Nagel, Du ¨ren, Germany) and reverse transcribed
with the M-MuLV reverse transcriptase (Finnzymes, Espoo,
Finland) using random heptanucleotides as primers. Polymerase
chain reactions were performed using the primers for endosialin
(endosialin_F2, R2), VEGF-A, b-actin and DyNAmo HS SYBR
Green qPCR Kit (Finnzymes). Following an initial denaturation at
951C for 10min, the amplification programme was set to
denaturation at 951C for 30s, annealing at 601C for 40s and
extension at 721C during 40s for a total of 40 cycles, and finally
5min at 721C.
Transient transfection and luciferase assay
The cells were plated into 35mm Petri dishes to reach
approximately 70% monolayer density on the next day. Transfec-
tion was performed with 2mg of pGL3-based promoter construct
and 100ng of pRL-TK plasmid DNAs using a GenePorterII reagent
(Genlantis). Alternatively, 1mg of pGL3-based promoter construct,
1mg of expression vector containing the transcription factor’s
cDNA and 50ng of pRL-TK plasmids were transfected. One day
later, the transfected cells were trypsinised and plated in triplicates
into 24-well plates. The cells were allowed to attach overnight and
then transferred to hypoxia for additional 24h. Reporter gene
expression was assessed using the Dual-Luciferase Reporter Assay
System (Promega) and the luciferase activity was normalised
against the renilla activity.
Immunoblotting
FIB-3 and 42-MG-BA cells were plated in sparse (12000 cellscm
 2)
or dense (48000 cellscm
 2) cultures, left to attach overnight and
then incubated for 24h in normoxia and hypoxia, respectively.
Proteins were extracted with cold RIPA buffer (1% Triton X-100,
0.1% sodium deoxycholate and 1x Complete protease inhibitor
cocktail (Roche, Mannheim, Germany) in PBS) for 15min at 41C,
and total protein concentrations were determined by BCA assay
(Pierce, Rockford, IL, USA). Samples of 50–80mg were separated
by SDS–PAGE and blotted onto the PVDF membrane. The
membrane was treated with M78 MAb in undiluted hybridoma
medium followed by the peroxidase-conjugated goat anti-mouse
immunoglobulins (DAKO, Glostrup, Denmark) and developed
using enhanced chemiluminescence. For loading control, the
membrane was probed with anti-a-tubulin antibody (rat mono-
clonal YL1/2, Novus Biologicals, Littleton, CO, USA) and the
polyclonal goat anti-rat IgG-HRP (Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
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RNA duplexes targeting HIF-1a (Hs_HIF1A_5 HP Validated
siRNA), HIF-2a (Hs_EPAS1_5 HP Validated siRNA) and negative
control siRNA were purchased from Qiagen (Qiagen AB, Solna,
Sweden). 42-MG-BA cells were transfected with 10nM siRNA using
HiPerFect reagent (Qiagen) according to the manufacturer’s
instructions. After 24h transfection, the medium was changed
and cells were transferred to hypoxia for additional 24h. Then,
proteins were extracted with cold high-salt buffer (50mM Tris-HCl
pH 7.4, 500mM NaCl, 1% NP-40 and 20% glycerol) supplemented
with 0.5mM PMSF and 5mM 2-mercaptoethanol for 30min at 41C.
Lysates were cleared by centrifugation for 30min at 16000g and
subjected to immunoblotting analysis as described above.
Chromatin immunoprecipitation assay
FIB-3 cells were plated into 500cm
2 plates at the density of 12000
cellscm
 2, left to attach overnight and incubated in absence or
presence of 100mM DIP for 4h and 24h. The cells were fixed in 1%
formaldehyde in PBS for 10min at room temperature. Chromatin
isolation, shearing to a size of B600–800bp and its immunopre-
cipitation with antibodies against HIF-1a (rabbit polyclonal, Santa
Cruz Biotechnology), HIF-1b (rabbit polyclonal, Mason et al, 1994)
and HIF-2a (rabbit polyclonal, Novus Biologicals), was performed
as described in Lo ¨fstedt et al, 2004. As a negative control and for
chromatin preclearing, anti-human IgG antibodies (rabbit poly-
clonal, Abcam, Cambridge, UK) were used. Purified DNA was
subjected to 36 cycles of PCR with primers flanking the putative
hypoxia-responsive elements (HREs) ( 1072HRE,  976HRE,
 574HRE) and Ets-binding sites ( 171/ 133-EBS) within the
endosialin promoter. Primers flanking the HRE of the VEGF
promoter were used as a positive control.
Bioinformatics
In silico analysis of the endosialin promoter was performed using
rVISTA 2.0 (Loots and Ovcharenko, 2004) and MatInspector
(Quandt et al, 1995) programs.
RESULTS
Hypoxia induces expression of endosialin
In initial experiments we examined the effect of hypoxia on
expression of endosialin in two human cell lines, namely FIB-3
placental fibroblasts and 42-MG-BA glioblastoma cells. The cells
were exposed to hypoxia (2% O2) for 24h, and parallel samples
were incubated for the same time period in normoxia. In both cell
lines, the endosialin gene showed increased expression in hypoxic
conditions as demonstrated by qRT–PCR (Figure 1A). We then
verified the hypoxic induction of endosialin at the protein level
using our specific MAb M78 generated against HeLa cells
transfected with the endosialin cDNA. The M78 MAb could
recognise a B95kDa core protein as well as a 165kDa glycosylated
form of endosialin (Figure 1B) and detected higher endosialin level
(especially that of the core protein) in cells exposed to hypoxia
than in normoxic cells (Figure 1C). These initial experiments
represented a proof-of-concept and prompted us to analyse the
transcriptional regulation of endosialin.
HIF-2 transcription factor mediates hypoxic induction of
endosialin
Computer analysis of a 2kb fragment of the 50 flanking region of
the human endosialin gene revealed several putative HRE with the
core sequence 50-RCGTG-30, both in sense and antisense orienta-
tions. Out of these, three HREs at positions  1072/ 1065,  976/
 969 and  574/ 567 (numbered with respect to the transcription
initiation site) were predicted as the conserved binding sites for
the transcription factors of the HIF family.
Therefore, we cloned the  1091/þ43 region of the human
endosialin gene into the promoter-less pGL3-basic vector and
analysed its activity in a dual luciferase reporter assay. Initial
attempts to perform the promoter analyses in endosialin-positive
human cell lines were hampered by low survival of these cells
following transfection. For this reason, we decided to use the
endosialin-negative HeLa cells that are easy to transfect and have
been frequently used in studies of HIF-mediated signalling. To
prove that these cells enable proper transcriptional responses of
the endosialin promoter, we included for comparison two mouse
cell lines, namely NIH3T3 fibroblasts and b.END3 endothelial cells
that naturally express the endosialin gene. In all cases, hypoxic
treatment of the transfected cells led to an increased expression of
the firefly luciferase gene driven by the endosialin upstream
regulatory region when compared to the normoxic controls
(Figure 2A). The level of hypoxic response in HeLa cells was
similar to that observed in NIH3T3 and b.END3 cells. Thus, the
subsequent promoter experiments were mostly carried out using
this human cell line.
To test whether HIF family members are responsible for the
hypoxic activation of endosialin gene, we first analysed the activity
of the endosialin promoter in Hepa-1c4 cells deficient in HIF-1b
FIB3 42-MG-BA
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Figure 1 Expression of endosialin in response to hypoxia. (A) FIB-3 and
42-MG-BA cells were incubated for 24h in normoxic or hypoxic
conditions. Total RNA was extracted and expression of endosialin mRNA
was analysed by quantitative RT–PCR and normalized to b-actin levels.
Vascular endothelial growth factor (VEGF) mRNA was used as a positive
control. (B) Specificity of the monoclonal antibody (MAb) M78 for
endosialin protein was evaluated by immunoblotting using 42-MG-BA cells
that naturally express endosialin and HeLa cells transfected with endosialin
cDNA (HeLa-endosialin). Mock-transfected HeLa cells served as a negative
control. M78 MAb could recognise both the non-glycosylated core protein
(95kDa) and the highly glycosylated endosialin (165kDa). (C) Immuno-
blotting analysis of endosialin protein levels in FIB-3 (50mg total proteins/
lane) and 42-MG-BA cells (80mg total proteins/lane loaded due to lower
endosialin expression level, see part a). The cells were incubated for 24h in
hypoxia (2% oxygen, þ) or normoxia ( ). M78 MAb revealed increased
expression of endosialin in the hypoxic cells. a-Tubulin antibody was used
for a loading control.
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s(ARNT), a common heterodimerisation partner for HIF-1a and
HIF-2a. As expected, hypoxic induction of the endosialin promoter
was abrogated in the absence of functional HIF-1b, but
was restored when the  1091/þ43 promoter construct was
co-transfected with HIF-1b expression vector (data not shown).
We then analysed the response of the endosialin promoter to HIF-1
and HIF-2 transcription factors. HeLa cells were co-transfected with
the  1091/þ43 promoter construct together with HIF-1a and
HIF-2a expression vectors, respectively, or with an empty expres-
sion vector, and cultivated in normoxia or hypoxia for 24h. Co-
transfection with HIF-1a resulted in modest effects on endosialin
promoter activity. In contrast, expression of HIF-2a led to robust,
dose-dependent activation of the endosialin promoter both in
normoxia and in hypoxia demonstrating that HIF-2a has strong
functional activity on the endosialin promoter (Figure 2B and C).
These findings were further supported by RNA interference-
mediated knock-down of endogenous HIF-1a and HIF-2a, respec-
tively. Hypoxic 42-MG-BA glioblastoma cells transfected with the
specific siRNAs clearly showed reduced endosialin protein level
when compared to the cells transfected with the control siRNA
(Figure 2D). Moreover, the effect of HIF-2a knock-down was more
dramatic than that of HIF-1a, in line with the proposed predomi-
nant role of HIF-2a in endosialin regulation under hypoxia.
HIF-2 regulates the endosialin promoter by binding to
HRE  976/ 969
To identify regulatory elements that are responsible for the
hypoxia-dependent activation, we constructed a series of
50-deletion variants of the originally cloned endosialin promoter
region as well as a variant with a double-point mutation in the
putative HREs  1072/ 1065 and  976/ 969 (designated as
mutHRE). Luciferase activity driven by these promoter variants
was tested in HeLa cells incubated for 24h in hypoxia and
normoxia, respectively. As shown in Figure 3, maximal hypoxic
induction was detected with the promoter constructs containing
an intact  1091/ 919 region, indicating that HRE  1072/ 1065
and/or HRE  976/ 969 might participate in the HIF-mediated
response.
We next performed chromatin immunoprecipitation assays,
allowing for the analysis of transcription factors binding to their
cognate sequences in an innate context of the promoter. We used
FIB-3 cells, which naturally express the endosialin gene as well as
both the HIF-1a and HIF-2a subunits (data not shown). The cells
were treated for 4 and 24h, respectively, with 100mM DIP (a cell-
permeable iron chelator commonly used in the studies of hypoxic
responses due to inhibition of prolyl and asparaginyl hydro-
xylases) to induce stable and transcriptionally active HIF proteins.
After treatment, the cells were fixed with formaldehyde, their
chromatin was isolated, sheared and immunoprecipitated with
antibodies directed to all three subunits of HIF-1 and HIF-2
transcription factors. Precipitated DNA fragments were purified
and used in PCRs together with primers flanking the putative HRE
 1072/ 1065 and HRE  976/ 969 sites, as well as the HRE  574/
 567 site. Primers flanking the HRE  982/ 975 in the VEGF
promoter were used for a positive control. We found that only the
endosialin HRE  976/ 969 showed a consistent signal for HIF-1a,
HIF-2a and HIF-1b in DIP-treated cells when compared to
HeLa NIH3T3 b.END3 4
3
2
1
0
F
o
l
d
 
i
n
d
u
c
t
i
o
n
F
o
l
d
 
i
n
d
u
c
t
i
o
n
pGL3 pGL3 pGL3 –1091/+43 –1091/+43 –1091/+43
Normoxia Hypoxia
30
20
10
0
pcDNA3.1 HIF-1 
HIF-2  HIF-2  siRNA
 -Tubulin
HIF-1  siRNA
HIF-2 
30
20
10
0
F
o
l
d
 
i
n
d
u
c
t
i
o
n
pcDNA3.1 1  g 0.75  g
0.25  g
0.5  g
0.5  g1    g
− −
−−
−−
−
−
Control siRNA +
+
+
Mw
250
150
100
48.5
42-MG-BA Endosialin
95 kDa
165 kDa
Figure 2 Effects of hypoxia, hypoxia-inducible factor (HIF)-1a and HIF-2a on the activity of endosialin promoter. (A) HeLa, NIH 3T3 and b.END3 cells
were transfected with the  1091/þ43 promoter fragment in pGL3-basic luciferase vector (2mg) and pRL-TK plasmid (100ng). The transfected cells were
incubated for 24h in normoxia or hypoxia. Luciferase activity was normalised against renilla activity. Hypoxic values were expressed as a fold induction of the
normoxic ones. Empty pGL3-basic plasmid was used for control of basal luciferase activity. Similar hypoxic induction was observed in all three cell lines.
(B) HeLa cells were co-transfected with the  1091/þ43 pGL3-basic promoter construct (1mg), pRL-TK plasmid (50ng), and HIF-1a or HIF-2a expression
vectors (1mg each). Empty pcDNA3.1 was used to adjust total DNA content in the control sample. The transfected cells were treated in normoxia and
hypoxia and the promoter activity was assessed as described above. HIF-2a but not HIF-1a dramatically induced endosialin promoter activity. (C) HeLa cells
were co-transfected with constant amounts of the  1091/þ43 pGL3-basic promoter construct (1mg) and pRL-TK plasmid (50ng), and an increasing
amount of HIF-2a expression vector. Total DNA was adjusted with empty pcDNA3.1. Endosialin promoter activities were assessed as above and showed a
dose-dependent induction by HIF-2a. The induction was more prominent in hypoxia apparently due to both stabilisation and activation of HIF-2a protein.
(D) Immunoblotting analysis of endosialin protein level in the 42-MG-BA cells transfected with the specific HIF-1a, HIF-2a and control siRNAs and incubated
under hypoxia for 24h. Both forms of endosialin were decreased after treatment with HIF-1a and HIF-2a siRNAs, respectively, but the effect of HIF-2a
siRNA was more evident suggesting a predominant role of HIF-2 in control of endosialin expression.
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suntreated control cells (Figure 4). In a manner similar to the
co-transfection experiments, the signals resulting from immuno-
precipitation with the anti-HIF-2a antibody were stronger
than those with the anti-HIF-1a antibody, suggesting that
HIF-2 may be a dominant factor in regulation of the endosialin
promoter.
HIF-2 cooperates with Ets-1
Recently it was reported that a small group of genes, regulated by
HIF-2 rather than HIF-1, have at least one HRE in proximity to an
ETS transcription factor-binding site (EBS) and that HIF-2a and
ETS-family member physically interact and cooperate in regulation
of these genes (Aprelikova et al, 2006). Consistent with this
concept, two putative EBS elements were found in the endosialin
promoter less than 80bp downstream of HRE  976/ 969 at
positions  935/ 919 and  907/ 891. Moreover, co-transfection
of the  1091/þ43 endosialin promoter construct with an
expression vector encoding a representative member of ETS
family, Ets-1, resulted in augmented endosialin promoter activity
indicating that Ets-1, in fact, contributes to regulation of
endosialin gene expression (Figure 5A).
To assess possible cooperation between Ets-1 and HIF-2 in
regulation of endosialin gene expression, we co-transfected HeLa
cells with the  1091/þ43 promoter construct and Ets-1 and
HIF-2a expression vectors either separately or together. Note-
worthy, the combined activating effect of Ets-1 and HIF-2a was
about 2.5 times higher than that calculated for an additive effect
of these two transcription factors expressed individually. This fact
suggests that Ets-1 and HIF-2a act synergistically to transactivate
endosialin transcription (Figure 5A). Furthermore, the  919/þ43
promoter fragment lacking EBS  935/ 919 displayed reduced
activation of the endosialin promoter by Ets-1 in the presence of
HIF-2a (Figure 5A), whereas no further reduction was observed
when EBS  907/ 891 was deleted (not shown). These data
strongly suggest that hypoxic induction of endosialin gene is
governed by HIF-2 transcription factor cooperating with Ets-1 by
adjacent HRE  976/ 969 and EBS  935/ 919 elements.
Nonetheless, the existence of the functional HRE nearly 1kb
upstream of the transcription start site could not explain our
observation that shorter promoter constructs lacking the classical
HRE sequence still remained partly hypoxia-responsive (Figure 3).
Moreover, in the absence of any apparent HRE, these constructs
responded to co-transfection with the HIF-2a expression vector by
increased reporter gene activity (Figure 5B). Interestingly, a similar
situation was described for the core promoter of VE-cadherin
gene that was transactivated by HIF-2a cooperating with Ets-1 by
two EBS elements (Le Bras et al, 2007). Indeed, the endosialin
promoter was found to contain two additional EBS motifs: the first
one designated as Ets-1 or ELF-2-binding site (EBS  171/ 156),
the other one as GABP-binding site (EBS  149/ 133). To
investigate whether any of these putative sites is functional, we
deleted either EBS  171/ 156 alone or both EBS elements from
the  235/þ43 fragment and co-transfected HeLa cells with the
resulting promoter constructs in the absence or presence of Ets-1
and HIF-2a vectors. As shown in Figure 5B, induction of  235/
þ43 reporter gene activity caused by simultaneous as well as
individual expression of Ets-1 and HIF-2a was considerably
decreased following the deletion of EBS  171/ 156 and was
almost completely abolished when both EBS elements were
eliminated.
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Figure 4 The binding of hypoxia-inducible factor (HIF) subunits to hypoxia-responsive elements in the endosialin promoter. Chromatin
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cells were incubated with formaldehyde for crosslinking, DNA was extracted and immunoprecipitated with antibodies specific for HIF subunits or for human
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transcription factor on the  235/ 16 endosialin promoter region
by chromatin immunoprecipitation assays (Figure 5C). On the
basis of these results, we propose that hypoxic induction of the
endosialin promoter fragment lacking apparent HREs is mediated
by HIF-2 that acts in cooperation with the Ets-1 transcription
factor binding to both EBS elements.
SP1 activates endosialin promoter in dense cells
Given that high cell density increases the expression of the mouse
endosialin gene (Opavsky et al, 2001), we analysed the effect of cell
crowding on expression levels of the human endosialin gene by
qRT–PCR. As shown in Figure 6A, increased cell density led to
elevated expression of endosialin mRNA. Interestingly, endosialin
expression was reduced in cells subjected to gentle stirring
throughout the experiment to ensure proper oxygenation of the
cell monolayer and elimination of pericellular hypoxia, which
occurs in high density cultures (Sheta et al, 2001). This finding
indicates that the effect of cell density on endosialin expression is
partially mediated by pericellular hypoxia. To obtain further
insight into a potential mechanism of transcriptional control of the
human endosialin gene by cell density, we analysed the endosialin
promoter activity in HeLa cells grown in sparse vs dense
monolayers. We found that the  1091/þ43 and  235/þ43
promoter fragments showed more than two-fold higher activity in
dense cells when compared to the sparse culture (Figure 6B).
Conversely, the activity of the  48/þ43 promoter construct
was not modulated by cell density, suggesting that the density-
responsive regulatory region is localised upstream of the
nucleotide  48.
Computer analysis of the sequence between nucleotides  235
and  48 relative to the transcriptional start site revealed that this
region is GC-rich and possesses several SP1- and AP-2-binding
sites. Co-transfection of the  235/þ43 promoter construct with
either SP1 or AP-2 expression vectors clearly demonstrated that
SP1 (and not AP-2) plays a role in activation of the endosialin
promoter (Figure 6C). This conclusion was supported by
immunoblotting analysis, which showed that density-induced
induction of endosialin protein expression in 42-MG-BA cells
can be abrogated by the SP1 inhibitor mithramycin A (Figure 6D).
Interestingly, the effect of cell density on endosialin gene
expression could be observed both under normoxic and
hypoxic conditions. In hypoxia, cell density further augmented
the hypoxic induction, indicating that these regulatory mecha-
nisms may be integrated in modulation of endosialin expression
(Figure 6E).
DISCUSSION
Several studies have reported selective upregulation of endosialin
in the vasculature and activated fibroblasts of various human
tumours, and a link between endosialin expression and induced
angiogenesis has been proposed. However, the molecular mecha-
nisms that control endosialin expression have remained elusive
(Rettig et al, 1992; Brady et al, 2004; Davies et al, 2004; Madden
et al, 2004; Dolznig et al, 2005; MacFadyen et al, 2005; Huber et al,
2006).
In this study, we demonstrate for the first time that hypoxia,
which is a driving force of angiogenesis under both physiological
and pathological conditions, regulates endosialin gene transcrip-
tion and that the hypoxic induction is mediated predominantly by
the HIF-2 transcription factor. Our finding is compatible with the
expression pattern and target gene preference of the HIF-2a
subunit. In contrast to the structurally and functionally related
HIF-1a subunit that is ubiquitously expressed, HIF-2a is confined
to tissues and cell types, which also express endosialin, including
blood vessels, fibroblasts and glial cells (Wiesener et al, 2003). In
addition, HIF-2a (rather than HIF-1a) regulates a subset of genes
involved in angiogenic responses, such as Tie-2/TEK, VEGFR1
(Flt-1), VEGFR2 (Kdr/Flk-1), VE-cadherin, EPO and TGF-a (Tian
et al, 1997; Takeda et al, 2004; Elvert et al, 2003; Raval et al, 2005;
Le Bras et al, 2007). Moreover, the kinetics of endosialin induction
by hypoxia with a maximum level achieved during a 24h incu-
bation period as well as an optimal oxygen concentration between
2 and 5% (data not shown) better correspond to the temporal
profile and activation optimum of HIF-2a, which increases with
time at moderate-to-mild hypoxia, whereas HIF-1a stabilisation
occurs at lower oxygen concentration and its levels are reduced
at prolonged hypoxia (Lo ¨fstedt et al, 2007). Thus, the endosialin
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Figure 5 Cooperation between the hypoxia-inducible factor (HIF)-2 and
Ets-1 transcription factor. (A) HeLa cells were co-transfected with the
 1091/þ43 or  919/þ43 pGL3-basic promoter construct (1mg), pRL-
TK plasmid (50ng) and HIF-2a and/or Ets-1 expression vectors (1mg each).
Empty pcDNA3.1 was used to adjust total DNA content in all samples to
3mg. The transfected cells were incubated in hypoxia and the promoter
activity was assessed as described in Figure 2. Simultaneous expression of
HIF-2a and Ets-1 showed synergic effect on endosialin promoter activity.
(B) HeLa cells were transfected with the  235/þ43 pGL3-basic
promoter construct and its mutated variants with deletions of one
(D 174/ 147) or both (D 174/ 91) EBS elements, respectively, and
pRL-TK, HIF-2a and/or Ets-1 plasmids were co-transfected as above. The
graph shows the promoter activity obtained in hypoxic cells only, as a
similar profile was observed in the normoxic counterparts. (C) Chromatin
immunoprecipitation assay was performed on FIB-3 cells under same
conditions as described in Figure 4, except that primers flanking the ETS
transcription factor-binding site (EBS) elements were used to detect
binding of the HIF subunits. HIF-2a clearly bound to the EBS-containing
region.
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transcription factor.
In further support of this model, the Ets-1 transcription factor
contributes to activation of endosialin expression. Physical and
functional interaction between HIF-2 and ETS family members
appears to be required for the proper hypoxic regulation of several
HIF-2-target genes (Aprelikova et al, 2006). Here, we demonstrate
that HIF-2 cooperating with Ets-1 can transactivate the endosialin
promoter through two distinct regions: a distal region, possibly
serving as an enhancer and a proximal region representing the
core promoter. The distal region contains a module composed of
the functional HRE site and the adjacent Ets-1-binding site. In
such a constellation, HIF-2 can directly bind DNA and at the same
time interact with Ets-1 through the N-terminal transactivation
domain, as has been shown for the other HIF-2-target genes
including VEGFR2 (Elvert et al, 2003). The proximal region of the
endosialin promoter is hypoxia-responsive despite the absence of
any apparent HRE. On this part of the promoter, HIF-2 seems to
operate through the interaction with Ets-1 and its two cognate EBS
elements. The paradigm for this mode of HIF-2 action can be
found in VE-cadherin promoter (Le Bras et al, 2007).
The proximal promoter region mediates also a cell density-
dependent activation response. This effect is partly related to
pericellular hypoxia and as such might again involve HIF-2, the
stabilisation and activation of which requires just a mild lowering
of oxygen tension (Lo ¨fstedt et al, 2007). As the SP1 transcription
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 2) monolayers and incubated for 24h in normoxia. Gentle stirring was applied to dense cells to eliminate pericellular hypoxia. Total RNA
was extracted and expression of endosialin mRNA was analysed by quantitative RT–PCR and normalised to b-actin levels. Stirring reduced the density-
elevated expression of endosialin. (B) Endosialin promoter activity in sparse vs dense HeLa cells was assessed by transfection of  1091/þ43,  235/þ43
and  48/þ43 fragments in pGL3-basic vector (1mg) with pRL-TK plasmid (50ng) as described in Figure 2. Effect of density was not observed in the
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activity was assessed after 24h incubation in normoxia as described in Figure 2. SP1 but not AP-2 induced endosialin promoter activity. (D) Immunoblotting
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Figure 7 Schematic illustration of the molecular anatomy of the
endosialin promoter and regulatory pathways induced by hypoxia and cell
density. Distal part of the promoter contains adjacent hypoxia-responsive
element (HRE) and ETS transcription factor-binding site (EBS) element and
transmits hypoxic signalling through hypoxia-inducible factor (HIF)-2
directly binding to DNA and cooperating with Ets-1. Proximal part of
the promoter contains two EBS elements (but not HRE) and hypoxia
signalling is mediated by HIF-2 through Ets-1 and two EBS elements. High
cell density contributes to endosialin activation by means of SP1-binding
sites in the proximal promoter and partially feeds the hypoxic pathway by
pericellular hypoxia. Moreover, hypoxia might influence activation of
endosialin indirectly through HIF-1 that upregulates expression of Ets-1,
which in turn upregulates expression of SP1. On the basis of this model,
hypoxia and density cross-talk to induce endosialin transcription.
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sparse monolayer cell culture, and inhibition of SP1 reduces
induction of endosialin expression by high cell density, SP1 seems
to be a critical factor mediating this regulatory effect.
Thus, as schematically summarised in Figure 7, the transcription
factors HIF-2 and Ets-1 mediate hypoxic responses, whereas SP1
functions as a mediator of density effects. Importantly, there is a
cross-talk between these regulatory pathways. However, the
situation might be more complex, as SP1 was found to be a
transcriptional target of Ets-1 (Sato and Furukawa, 2007), and
Ets-1 expression is enhanced by HIF-1 (Oikawa et al, 2001). In the
case of endosialin expression, we observed that the gene is
regulated by hypoxia under conditions that stabilise and activate
HIF-2 and/or HIF-1. It is conceivable that HIF-1 does not need to
be directly bound to endosialin promoter to mediate this effect,
but induces Ets-1 expression and thus supports formation of the
cooperative complex between Ets-1 and HIF-2. Elevated expression
of Ets-1 then presumably leads to increased transcription of SP1,
which can further stimulate activity of endosialin promoter.
The involvement of hypoxia in regulation of endosialin gene
expression sheds new light on its possible biological significance in
vascular remodelling. According to recent data, endosialin is
preferentially associated with pericytes and stromal fibroblasts, but
not with endothelial cells, as suggested in earlier studies
(MacFadyen et al, 2005; Christian et al, 2008; Simonavicius et al,
2008). Pericytes form an outer sheath around the endothelium and
play an important role in maturation of blood microvessels and
stabilisation of vascular network, whereas stromal fibroblasts
stimulate angiogenesis by trophic effects and extracellular matrix
reorganisation (Jain, 2003; Armulik et al, 2005). In contrast to
normal tissues, tumours are characterised by continuously on-
going angiogenesis with high proliferation rate of endothelial cells
and diminished maturation of blood vessels (Bergers and
Benjamin, 2003). The functionally defective vasculature gives rise
to hypoxia in the tumour tissue, resulting in excessive production
of proangiogenic factors and a new round of angiogenesis
accompanied by tumour expansion. To allow for a new blood
vessel formation, the pericytes of pre-existing vessels have to be
detached from endothelial cells and enable them to respond to
mitogenic signals. It is possible that hypoxia (and also dense
intercellular contacts) upregulate expression of endosialin to
relieve pericyte–endothelial interactions and/or to modulate local
tumour stroma, and thereby facilitate migration of dividing
endothelial cells and sprouting of new blood vessels. Indeed,
endosialin was found to support an invasive tumour phenotype in
the mouse knock-out model and modulate in vitro migration,
which are phenomena well known to be linked to hypoxia and
angiogenesis (Nanda et al, 2006; Tomkowicz et al, 2007). This
hypothesis could also explain why endosialin expression is
detectable in the developing embryo, where new blood vessels
form to feed extensive hypoxic areas, but not in adult tissues,
where hypoxia is generally absent, and vascular network is usually
mature and quiescent.
Although further functional studies are clearly required to prove
the above-proposed role for endosialin, this study clarifies
important aspects of its regulation and provides a rational frame
for future investigations towards a better understanding of its
biological significance.
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